Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Zydus Lifesciences Ltd is up for a fifth straight session today. The stock is quoting at Rs 994.45, up 1.46% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.07% on the day, quoting at 24697.95. The Sensex is at 80903.8, up 0.02%. Zydus Lifesciences Ltd has gained around 0.45% in last one month.
Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has gained around 4.31% in last one month and is currently quoting at 22761.15, up 1% on the day. The volume in the stock stood at 3.25 lakh shares today, compared to the daily average of 8.66 lakh shares in last one month.
The benchmark July futures contract for the stock is quoting at Rs 997, up 1.7% on the day. Zydus Lifesciences Ltd is down 18.45% in last one year as compared to a 0.64% slide in NIFTY and a 6.72% slide in the Nifty Pharma index.
The PE of the stock is 17.14 based on TTM earnings ending March 25.
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg (USRLD: Imbruvica® tablets, 140 mg, 280 mg and 420 mg).
Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, and Waldenstrom's macroglobulinemia (WM). Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad.
Ibrutinib tablets had annual sales of USD 2148.9 mn in the United States (IQVIA MAT May 2025).
The group now has 420 approvals and has so far filed 484 ANDAs since the commencement of the filing process in FY 2003-04.
Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) with a 17p deletion, and Waldenström's macroglobulinemia (WM).
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. The tablets had annual sales of $2,148.9 million in the United States (IQVIA MAT May 2025).
The group now holds 420 approvals and has filed a total of 484 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company’s consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24.
Shares of Zydus Lifesciences rose 0.78% to currently trade at Rs 969.15 on the BSE.